Login to Your Account



Pharmacyclics: New Phase III Sharpens Cancer Drug’s Focus

By Randall Osborne


Wednesday, April 17, 2002
Pharmacyclics Inc. is planning a new Phase III trial of its cancer cell disrupter, Xcytrin, in the sector of patients for whom the drug seems to do the most good those with lung cancer that has metastasized to the brain. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription